BioCentury | May 12, 2003
Finance

Ebb & Flow

...for buyers of ORCH's recent $16 million preferred stock financing. In the deal, BayStar Capital, SDS Capital...
BioCentury | Apr 28, 2003
Finance

Ebb & Flow

...cream in erectile dysfunction don't pan out. Data are expected this quarter. The syndicate includes SDS Capital...
BioCentury | Apr 2, 2003
Financial News

Orchid raises $16 million

...through the sale of 1,600 shares of convertible preferred stock at $10,000 to BayStar Capital; SDS Capital...
BioCentury | Nov 6, 2002
Financial News

Discovery Laboratories raises $12.8 million

...financing was led by BioAsia Investments. Other investors included Heartland Value Fund; Special Situations Funds; SDS Capital...
BioCentury | Nov 13, 2000
Finance

Schroder's plans for IBT

...end-product (A.G.E.) compound in cardiovascular disease. The investors, including S.A.C. Capital, Narragansett Asset Management and SDS Capital...
Items per page:
1 - 5 of 5
BioCentury | May 12, 2003
Finance

Ebb & Flow

...for buyers of ORCH's recent $16 million preferred stock financing. In the deal, BayStar Capital, SDS Capital...
BioCentury | Apr 28, 2003
Finance

Ebb & Flow

...cream in erectile dysfunction don't pan out. Data are expected this quarter. The syndicate includes SDS Capital...
BioCentury | Apr 2, 2003
Financial News

Orchid raises $16 million

...through the sale of 1,600 shares of convertible preferred stock at $10,000 to BayStar Capital; SDS Capital...
BioCentury | Nov 6, 2002
Financial News

Discovery Laboratories raises $12.8 million

...financing was led by BioAsia Investments. Other investors included Heartland Value Fund; Special Situations Funds; SDS Capital...
BioCentury | Nov 13, 2000
Finance

Schroder's plans for IBT

...end-product (A.G.E.) compound in cardiovascular disease. The investors, including S.A.C. Capital, Narragansett Asset Management and SDS Capital...
Items per page:
1 - 5 of 5